Ask AI
ProCE Banner Activity

CAR T-Cell Therapy: What Oncology Nurses Need to Know About Long-Term AEs

Clinical Thought

As data have continued to evolve, CAR T-cell therapy has expanded into earlier lines of treatment and important FDA safety and monitoring updates are reshaping postinfusion care. Let’s talk about practical, nurse-centered guidance for patient selection, acute toxicity recognition, and long-term surveillance for cytopenias, infections/hypogammaglobulinemia, and delayed neurologic effects.

Released: December 17, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson

Target Audience

This activity has been designed to meet the educational needs of community oncology nurses, nurse practitioners, and other healthcare professionals who care for patients treated with CAR T-cell therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients at increased risk for long-term toxicities related to CAR T-cell therapy

  • Counsel patients and caregivers on the onset, symptoms, and clinical manifestations of short-term vs long-term toxicities related to CAR T-cell therapy

  • Implement strategies to monitor for and manage long-term toxicities in patients treated with CAR T-cell therapy based on the latest guidelines, expert recommendations, and evidence

  • Develop plans for transitioning care from the CAR T-cell treating center to community practice that optimize the patient’s long-term safety and quality of life

Disclosure

Primary Author

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO: consultant/advisor/speaker: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi.